MSFP
ALNY icon

Mark Sheptoff Financial Planning’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01K Hold
10
– – ﹤0.01% 479
2026
Q1 		$3.01K Hold
10
– – ﹤0.01% 467
2025
Q4 		$3.98K Hold
10
– – ﹤0.01% 452
2025
Q3 		$4.56K Hold
10
– – ﹤0.01% 419
2025
Q2 		$3.26K Hold
10
– – ﹤0.01% 431
2025
Q1 		$2.7K Hold
10
– – ﹤0.01% 402
2024
Q4 		$2.35K Hold
10
– – ﹤0.01% 395
2024
Q3 		$2.75K Hold
10
– – ﹤0.01% 387
2024
Q2 		$2.43K Hold
10
– – ﹤0.01% 386
2024
Q1 		$1.5K Buy
+10
New +$1.67K ﹤0.01% 369

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mark Sheptoff Financial Planning's ALNY Position: Q2 2026 in Review

Mark Sheptoff Financial Planning held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 10 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

Mark Sheptoff Financial Planning first reported a position in ALNY in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.56K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Mark Sheptoff Financial Planning held 10 shares of Alnylam Pharmaceuticals worth $3.01K as of Q2 2026.
  • Mark Sheptoff Financial Planning left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q2 2026, its #479 holding.
  • Mark Sheptoff Financial Planning first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Mark Sheptoff Financial Planning's Alnylam Pharmaceuticals position peaked at $4.56K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2026, filed 13 Aug 2026.